Image source: Getty Images.
Continue Reading Below
After reporting fiscal-quarter results shy of industry watchers' expectations and offering a cautious view of future drug price trends, shares in McKesson Corporation(NYSE: MCK) are falling 24% at 1:00 p.m. EST today.
McKesson is one of the largest drug distributors in the United States, and after the bell yesterday, management reported that fiscal second-quarter sales inched up just 2% to $50 billion, and that adjusted EPS was $2.94. Both of those figures were shy of analysts' consensus forecasts. Industry watchers were hoping for $51.2 billion in sales and $3.05 in EPS.
The under-performance stems largely from fallout tied to growing payer pushback on generic and brand-name drug price increases. McKesson entered its fiscal year recognizing that scrutiny, which surged last year in the wake of revelations of unchecked price increases on long-standing drugs, would crimp growth opportunities; however, it appears management's assumptions weren't pessimistic enough, and that deflationary drug price pressure from customers is increasing as revenue from brand-name drug price increases falls.
Continue Reading Below
John Hammergren, McKesson's CEO, summarized:
In our first quarter, we witnessed some evidence of inflation and pricing softness in line with our original assumptions. However, this softness became much more pronounced in our second quarter, first around brand inflation and later, around customer pricing.
McKesson inks contracts with brand-name drugmakers that include chargesderived as a percent of revenue managed and delivered by McKesson. These charges vary by manufacturer and service level, but the tie to drug revenue means drug price inflation (or lack thereof) can meaningfully affect results. Thus, a slowing in brand-name drug price increases is presenting a headwind this year.
Hammergren's team has remodeled its expectations for the year based on those challenges, and they now believe pricing and brand-name drug inflation will be a negative $1.60 to $1.90 per share drag on fiscal-year results. The company should be able to offset some of that, but it won't be able to overcome all of it, and as a result, McKesson has adjusted its EPS guidance for fiscal 2017 lower to between$12.35 to $12.85 from prior forecasts for between$13.43 to $13.93.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early, in-the-know investors! To be one of them, just click here.
Todd Campbell has no position in any stocks mentioned.Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Like this article? Follow him onTwitter where he goes by the handle @ebcapitalto see more articles like this.
The Motley Fool recommends McKesson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.